Skip to main content
. 2014 Mar 24;9(3):e92626. doi: 10.1371/journal.pone.0092626

Figure 10. Kinetics of EPCs for neovascularization in vivo.

Figure 10

(A) Representative fluorescence microscopic images of EPCs incorporated in endothelial cells of the ischemic limbs of athymic nude rats 60 h after intramuscular injection of EPCs, NT-EPCs, or FOXO4KD-EPCs. Rat specific CD31-positive endothelial cells were stained red. Human specific PCNA-positive cells, which were defined as human-derived EPCs, were stained green. Scale bar: 50 μm. (B) Pooled data of the number of PCNA-positive EPCs incorporated in endothelial cells of the rat ischemic limbs 60 h after the injection of EPCs, NT-EPCs, or FOXO4KD-EPCs (*: p<0.01; **: p<0.005; n = 5, each). (C) A representative western blotting photo of expressions of human specific VEGF, b-FGF, SDF-1, and IGF-1 in the rat ischemic limb 60 h after intramuscular injection of EPCs, NT-EPCs, or FOXO4KD-EPCs (n = 4, each).